Clinical trials: Cancer Disease Progression
Glioblastoma, Glioblastoma Multiforme
Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma
The primary aim of this project is to Compare new msCS and standard DSC-PWI methods in GBM patients undergoing post-operative MRI for monitoring of tumor progression.
- Trial name
- NCT02769806
- Testing
- MRI
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Wisconsin, Madison
Lung Cancer, Melanoma
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab…
- Conditions
- Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer
- Trial name
- NCT02586987
- Testing
- Selumetinib, MEDI4736, Tremelimumab
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Brain Tumors, Solid Tumor
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Honest, clear, and empathetic communication between pediatric oncologists (POs) and parents of children with cancer (POCCs) is imperative to facilitating therapeutic alliance and ensuring that medical management aligns with the…
- Trial name
- NCT02846038
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- St. Jude Children's Research Hospital
Myasthenia Gravis
Clinical Prognosis and Progression of Myasthenia Gravis Patients
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.
- Trial name
- NCT04101578
- Testing
- Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Da, Yuwei, M.D.
Smoldering Multiple Myeloma
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation.
- Trial name
- NCT02415413
- Testing
- carfilzomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in Spain
- Volunteers
- 90 people
- Sponsor
- PETHEMA Foundation
Cancer, Ovarian Cancer
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.
- Conditions
- Cancer, Ovarian Cancer, Solid Tumor
- Trial name
- NCT00753740
- Testing
- IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose)
- Where
- 7 sites in United States
- Sponsor
- NewLink Genetics Corporation
Brain Tumors
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
The study PNET 5 MB has been designed for children with medulloblastoma of standard risk (according to the risk-group definitions which have been used so far; e.g. in PNET 4).
- Trial name
- NCT02066220
- Testing
- Radiotherapy without Carboplatin, Reduced-intensity maintenance chemotherapy, Radiotherapy with Carboplatin
- Where
- 77 sites in Austria, Belgium and 14 more
- Volunteers
- 360 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Non-Small Cell Lung Cancer
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged
To determine the detection rate of driver oncogenes and resistance mechanisms in cerebrospinal fluid (CSF) for patients with CNS progression (with or without extra-CNS (eCNS) progression) and concordance with plasma/tissue
- Trial name
- NCT05116618
- Testing
- InVisionFirst-Lung ctDNA assay
- Where
- 3 sites in United States
- Sponsor
- University of Colorado, Denver
Prostate Cancer
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
Prostate cancer (PCa) is the most common non-skin malignancy and the third leading cause of cancer death in North American men. The accurately mapped metastatic state is a necessary prerequisite to guiding treatment in practice…
- Trial name
- NCT03594760
- Testing
- 18F-DCFPyL IV injection
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Multiple Myeloma
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
- Trial name
- NCT02578121
- Testing
- Ixazomib, Pomalidomide, Dexamethasone
- Where
- United States
- Sponsor
- University of Arkansas
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation
Radiomics for Diagnosing Liver Diseases and Evaluating Progression
Liver diseases are worldwide problems. liver fibrosis and hepatocellular carcinoma are mostly concerned by clinicians. Radiomcis can improve diagnosis accuracy and evaluate disease progression.
- Trial name
- NCT03221049
- Testing
- radiomics
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Sarcoma
Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
This is a randomized open label study, with 2 arms treatments conducted in patients with metastatic or unresectable advanced sarcoma of rare subtype; previously treated by anthracycline-based regimen except for whom standard…
- Trial name
- RAR-Immune (NCT04741438)
- Testing
- Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
- Where
- 13 sites in France
- Volunteers
- 96 people
- Sponsor
- Centre Leon Berard
Rectal Neoplasms
Watch and Wait as Treatment for Patients With Rectal Cancer
A national cohort study with all patients scheduled for neoadjuvant treatment with (chemo)radiotherapy or short course radiotherapy with delayed surgery 6-8 weeks) for rectal cancer staged as cT4bNX/anycTanycN and…
- Trial name
- WoW (NCT03125343)
- Testing
- endoscopy, Surgery, MRI
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Stromal Tumor
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.
- Trial name
- NCT01110668
- Testing
- Nilotinib
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Adenoid Cystic Carcinoma, Progressive Disease
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body.
- Conditions
- Metastatic Adenoid Cystic Carcinoma, Progressive Disease, Recurrent Adenoid Cystic Carcinoma
- Trial name
- NCT03990571
- Testing
- Avelumab, Axitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Mesothelioma, Malignant, PD-L1 Negative
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Pembrolizumab plus autologous dendritic cell vaccine in patients with PD-L1 negative advanced mesothelioma who have failed prior therapies.This is an exploratory, single-arm, open-label, phase 1b clinical trial.
- Conditions
- Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
- Trial name
- MESOVAX (NCT03546426)
- Testing
- Pembrolizumab, Autologous dendritic cells, Interleukin-2
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Anaplastic Ependymoma, Ependymoma
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Background: Ependymomas are rare tumors that arise from the ependyma. That is a tissue of the central nervous system. They can develop in the brain or the spine.
- Conditions
- Anaplastic Ependymoma, Ependymoma, Ependymomas
- Trial name
- NCT03727841
- Testing
- Marizomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study will evaluate the efficacy and safety of adding bevacizumab to crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer who have experienced disease progression under first line…
- Trial name
- NCT00700102
- Testing
- Chemotherapy, Bevacizumab
- Where
- 300 sites in Austria, Belgium and 13 more
- Volunteers
- 820 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.